UEG Week Recordings UEG Week Posters Online courses Guidelines Mistakes in... Podcasts Webinars
new
Gut Guide online
Visit ueg.eu Create myUEG account Log In
Visit ueg.eu Create myUEG account Log In

Filters:

UEG Online Course
accredited
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

GORD Pathophysiology - Part 1

Daniel Sifrim, Kornilia Nikaki

Summary

AI Generated

An online course examines the multifactorial pathophysiology of gastro-oesophageal reflux disease by following the path of the refluxate through the stomach, antireflux barrier, clearance mechanisms, mucosa and symptom perception.

  • The pathophysiology of GORD is now understood to be multifactorial, evolving from earlier views that equated GORD with oesophagitis and hiatal hernia to include transient lower oesophageal sphincter relaxations, different phenotypes and microscopic features.
  • The course covers individual pathophysiological components including the stomach, antireflux barrier, refluxate, clearance mechanisms, mucosa and symptom perception.
  • A key learning objective is that patients with different GORD phenotypes may have different underlying pathophysiological mechanisms and may require different treatments even when presenting with similar symptoms.
  • The course is suitable for gastroenterologists in training, physicians and surgeons in other disciplines, nurses, biotechnicians and advanced-years medical students with an interest in gastroenterology.
Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Overview

The diagnosis and treatment of gastro-oesophageal reflux disease (GORD) have been driven by our knowledge of its pathophysiology. From equating GORD with oesophagitis and hiatal hernia to identifying the role of transient lower oesophageal sphincter relaxations, different GORD phenotypes and microscopic features, the pathophysiology is now understood to be multifactorial.

This online course covers the different components that contribute to the pathophysiology of GORD by following the path of the refluxate. The role of the stomach, antireflux barrier, refluxate, clearance mechanisms, mucosa and symptom perception are each considered in turn.  

Learning objectives

  • To understand that the pathophysiology of GORD is multifactorial
  • To become familiar with each of the individual pathophysiology abnormalities
  • To realize that patients with different GORD phenotypes may have different underlying pathophysiological mechanisms
  • To recognize that treatment of GORD should be designed to modify the specific pathophysiology
  • To appreciate that patients with GORD who have similar symptoms but different pathophysiology mechanisms may need different treatments

Target audience

This course is suitable for gastroenterologists in training, but is also appropriate for physicians and surgeons in other disciplines, as well as nurses, biotechnicians and advanced-years’ medical students who have an interest in gastroenterology. 

Reviewed & updated February 2023

Event

GORD Pathophysiology Part 1

Topics

Neurogastroenterology & Motility Oesophagus

Accreditation status

accredited

Duration

1 hour

Published

2018

More Like This:

Desmoplasia in liver cancer: translating tumour microenvironment insights into clinical practice

Desmoplasia in liver cancer: translating tumour microenvironment insights into clinical practice

Silvia Affò Silvia Affò

Is ageing a metabolic disease?

Is ageing a metabolic disease?

Amalia Gastaldelli Amalia Gastaldelli

Metabolic syndrome

Metabolic syndrome

Helena Cortez-Pinto Helena Cortez-Pinto

Fatty pancreas

Fatty pancreas

Miroslav Vujasinovic Miroslav Vujasinovic

THE PEPPER TRIAL: WHAT TO EXPECT WHEN STOPPING CHRONIC PROTON PUMP INHIBITOR THERAPY IN PRIMARY CARE PATIENTS

THE PEPPER TRIAL: WHAT TO EXPECT WHEN STOPPING CHRONIC PROTON PUMP INHIBITOR THERAPY IN PRIMARY CARE PATIENTS

Florencia Carbone Florencia Carbone, Jan Tack, Annouschka Laenen, Karen Van den Houte, Janne Scheepers

INCRETIN-BASED THERAPIES IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS: COMPARATIVE HISTOLOGIC EFFICACY AND INTERNATIONAL GUIDELINE DISCORDANCE

INCRETIN-BASED THERAPIES IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS: COMPARATIVE HISTOLOGIC EFFICACY AND INTERNATIONAL GUIDELINE DISCORDANCE

Tyler Black Tyler Black, Adam Edwards, Samuel Tarwater, Benjamin Hewitt, Paul Lamb, Travis Rutland, Beth Rutland, Rowan Bandaranaike

UEG Presentation
New
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky
Desmoplasia in liver cancer: translating tumour microenvironment insights into clinical practice

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Desmoplasia in liver cancer: translating tumour microenvironment insights into clinical practice

Silvia Affò 1

Affiliations

1 Fundació de Recerca Clínic Barcelona, Barcelona, Spain

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Event

UEG Week Barcelona 2026

Topics

Digestive Oncology Pancreas Mechanisms & Personalised Medicine

Session

Translating metabolic insights into clinical practice: Key lessons for gastroenterologists

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

Desmoplasia in liver cancer: translating tumour microenvironment insights into clinical practice

Desmoplasia in liver cancer: translating tumour microenvironment insights into clinical practice

Silvia Affò Silvia Affò

Is ageing a metabolic disease?

Is ageing a metabolic disease?

Amalia Gastaldelli Amalia Gastaldelli

Metabolic syndrome

Metabolic syndrome

Helena Cortez-Pinto Helena Cortez-Pinto

Fatty pancreas

Fatty pancreas

Miroslav Vujasinovic Miroslav Vujasinovic

THE PEPPER TRIAL: WHAT TO EXPECT WHEN STOPPING CHRONIC PROTON PUMP INHIBITOR THERAPY IN PRIMARY CARE PATIENTS

THE PEPPER TRIAL: WHAT TO EXPECT WHEN STOPPING CHRONIC PROTON PUMP INHIBITOR THERAPY IN PRIMARY CARE PATIENTS

Florencia Carbone Florencia Carbone, Jan Tack, Annouschka Laenen, Karen Van den Houte, Janne Scheepers

INCRETIN-BASED THERAPIES IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS: COMPARATIVE HISTOLOGIC EFFICACY AND INTERNATIONAL GUIDELINE DISCORDANCE

INCRETIN-BASED THERAPIES IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS: COMPARATIVE HISTOLOGIC EFFICACY AND INTERNATIONAL GUIDELINE DISCORDANCE

Tyler Black Tyler Black, Adam Edwards, Samuel Tarwater, Benjamin Hewitt, Paul Lamb, Travis Rutland, Beth Rutland, Rowan Bandaranaike

UEG Presentation
New
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky
Is ageing a metabolic disease?

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Is ageing a metabolic disease?

Amalia Gastaldelli 1

Affiliations

1 Institute of Clinical Physiology, Pisa, Italy

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Event

UEG Week Barcelona 2026

Topics

Mechanisms & Personalised Medicine

Session

Ageing of the patient: Does metabolism matter?

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

Desmoplasia in liver cancer: translating tumour microenvironment insights into clinical practice

Desmoplasia in liver cancer: translating tumour microenvironment insights into clinical practice

Silvia Affò Silvia Affò

Is ageing a metabolic disease?

Is ageing a metabolic disease?

Amalia Gastaldelli Amalia Gastaldelli

Metabolic syndrome

Metabolic syndrome

Helena Cortez-Pinto Helena Cortez-Pinto

Fatty pancreas

Fatty pancreas

Miroslav Vujasinovic Miroslav Vujasinovic

THE PEPPER TRIAL: WHAT TO EXPECT WHEN STOPPING CHRONIC PROTON PUMP INHIBITOR THERAPY IN PRIMARY CARE PATIENTS

THE PEPPER TRIAL: WHAT TO EXPECT WHEN STOPPING CHRONIC PROTON PUMP INHIBITOR THERAPY IN PRIMARY CARE PATIENTS

Florencia Carbone Florencia Carbone, Jan Tack, Annouschka Laenen, Karen Van den Houte, Janne Scheepers

INCRETIN-BASED THERAPIES IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS: COMPARATIVE HISTOLOGIC EFFICACY AND INTERNATIONAL GUIDELINE DISCORDANCE

INCRETIN-BASED THERAPIES IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS: COMPARATIVE HISTOLOGIC EFFICACY AND INTERNATIONAL GUIDELINE DISCORDANCE

Tyler Black Tyler Black, Adam Edwards, Samuel Tarwater, Benjamin Hewitt, Paul Lamb, Travis Rutland, Beth Rutland, Rowan Bandaranaike

UEG Presentation
New
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky
Metabolic syndrome

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Metabolic syndrome

Helena Cortez-Pinto 1

Affiliations

1 Faculdade de Medicina de Lisboa, Centro Hospitalar Lisboa Norte, HSM, Lisbon, Portugal

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Event

UEG Week Barcelona 2026

Topics

Digestive Oncology Pancreas Mechanisms & Personalised Medicine

Session

Translating metabolic insights into clinical practice: Key lessons for gastroenterologists

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

Desmoplasia in liver cancer: translating tumour microenvironment insights into clinical practice

Desmoplasia in liver cancer: translating tumour microenvironment insights into clinical practice

Silvia Affò Silvia Affò

Is ageing a metabolic disease?

Is ageing a metabolic disease?

Amalia Gastaldelli Amalia Gastaldelli

Metabolic syndrome

Metabolic syndrome

Helena Cortez-Pinto Helena Cortez-Pinto

Fatty pancreas

Fatty pancreas

Miroslav Vujasinovic Miroslav Vujasinovic

THE PEPPER TRIAL: WHAT TO EXPECT WHEN STOPPING CHRONIC PROTON PUMP INHIBITOR THERAPY IN PRIMARY CARE PATIENTS

THE PEPPER TRIAL: WHAT TO EXPECT WHEN STOPPING CHRONIC PROTON PUMP INHIBITOR THERAPY IN PRIMARY CARE PATIENTS

Florencia Carbone Florencia Carbone, Jan Tack, Annouschka Laenen, Karen Van den Houte, Janne Scheepers

INCRETIN-BASED THERAPIES IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS: COMPARATIVE HISTOLOGIC EFFICACY AND INTERNATIONAL GUIDELINE DISCORDANCE

INCRETIN-BASED THERAPIES IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS: COMPARATIVE HISTOLOGIC EFFICACY AND INTERNATIONAL GUIDELINE DISCORDANCE

Tyler Black Tyler Black, Adam Edwards, Samuel Tarwater, Benjamin Hewitt, Paul Lamb, Travis Rutland, Beth Rutland, Rowan Bandaranaike

UEG Presentation
New
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky
Fatty pancreas

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Fatty pancreas

Miroslav Vujasinovic 1

Affiliations

1 Karolinska University Hospital, Stockholm, Sweden

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Event

UEG Week Barcelona 2026

Topics

Digestive Oncology Pancreas Mechanisms & Personalised Medicine

Session

Translating metabolic insights into clinical practice: Key lessons for gastroenterologists

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

Desmoplasia in liver cancer: translating tumour microenvironment insights into clinical practice

Desmoplasia in liver cancer: translating tumour microenvironment insights into clinical practice

Silvia Affò Silvia Affò

Is ageing a metabolic disease?

Is ageing a metabolic disease?

Amalia Gastaldelli Amalia Gastaldelli

Metabolic syndrome

Metabolic syndrome

Helena Cortez-Pinto Helena Cortez-Pinto

Fatty pancreas

Fatty pancreas

Miroslav Vujasinovic Miroslav Vujasinovic

THE PEPPER TRIAL: WHAT TO EXPECT WHEN STOPPING CHRONIC PROTON PUMP INHIBITOR THERAPY IN PRIMARY CARE PATIENTS

THE PEPPER TRIAL: WHAT TO EXPECT WHEN STOPPING CHRONIC PROTON PUMP INHIBITOR THERAPY IN PRIMARY CARE PATIENTS

Florencia Carbone Florencia Carbone, Jan Tack, Annouschka Laenen, Karen Van den Houte, Janne Scheepers

INCRETIN-BASED THERAPIES IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS: COMPARATIVE HISTOLOGIC EFFICACY AND INTERNATIONAL GUIDELINE DISCORDANCE

INCRETIN-BASED THERAPIES IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS: COMPARATIVE HISTOLOGIC EFFICACY AND INTERNATIONAL GUIDELINE DISCORDANCE

Tyler Black Tyler Black, Adam Edwards, Samuel Tarwater, Benjamin Hewitt, Paul Lamb, Travis Rutland, Beth Rutland, Rowan Bandaranaike

UEG Presentation
New
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky
THE PEPPER TRIAL: WHAT TO EXPECT WHEN STOPPING CHRONIC PROTON PUMP INHIBITOR THERAPY IN PRIMARY CARE PATIENTS

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

THE PEPPER TRIAL: WHAT TO EXPECT WHEN STOPPING CHRONIC PROTON PUMP INHIBITOR THERAPY IN PRIMARY CARE PATIENTS

Janne Scheepers 1, Karen Van den Houte 1, Annouschka Laenen 1, Jan Tack 2, Florencia Carbone 1

Affiliations

1 KU Leuven, Leuven, Belgium

2 University of Leuven, University Hospital Gasthuisberg, Leuven, Belgium

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

Inappropriate long‑term use of proton pump inhibitors (PPIs) is common, with up to 82% of chronic prescriptions lacking a valid indication. Treatment is rarely tapered or discontinued once initiated. A key barrier to deprescribing is the (re-)occurrence of gastrointestinal symptoms, which often leads to treatment resumption. Moreover, insight into the long‑term evolution of individual symptoms following PPI discontinuation is lacking.

Aims & Methods

This study aimed to characterize the expected evolution of gastrointestinal symptoms during and after PPI deprescribing in primary care. In this pragmatic clinical trial, 61 general practitioners recruited and randomised patients to one of three PPI deprescribing strategies. After following the assigned strategy for 1 month, patients were requested to stop PPI use and were followed up for 1 year. Gastrointestinal symptom severity (PAGI-SYM) and quality of life (PAGI-QOL) were assessed at all timepoints. Antacids were allowed as rescue therapy throughout the trial. Successful patients were defined as limited those with PPI use (<4 doses per month) and willingness to continue their current treatment, from follow-up onward. Linear mixed models were used. Random effects were modelled to deal with the longitudinal data structure. The fixed effect model included time, group and time by group interactions. Analyses were performed on an ITT basis. Results are presented as mean±SD or median (IQR).

Results

627 patients were randomized (60±14 years old, BMI 28±5kg/m2, 60% female, median PPI use 9 (5-15) years). Following initiation of the deprescribing strategies, a transient increase in upper gastrointestinal symptoms was observed after one month of deprescribing. Compared to baseline, overall symptom severity increased significantly (p<0.0001), driven by worsening heartburn, nausea, postprandial fullness, early satiation, and upper abdominal pain (all p<0.0001). This increase was driven mainly by the increased symptom severity in unsuccessful patients, as the overall symptom severity did not increase in the successful patients. Notably, bloating severity decreased significantly from the month of deprescribing onward (p<0.0001) and continued to decline, resulting in lower bloating scores throughout the entire follow‑up period compared with baseline. During the follow-up period, overall PAGI‑SYM scores improved to below baseline levels (p<0.0001). Postprandial fullness and early satiation improved significantly from 3 months follow-up onward (p=0.0005), accompanied by improvement in lower abdominal pain (p=0.0060). Upper abdominal pain decreased significantly from 6 months follow-up onward (p=0.0047). No significant differences in symptom pattern are seen based on the initial PPI indication. Quality of life improved from the follow-up period onward (p<0.0001).

Conclusion

PPI deprescribing in long‑term users is associated with a short‑term transient increase in upper gastrointestinal symptoms, followed by progressive and sustained symptom improvement over time. Quality of life and multiple symptom domains improve beyond baseline at follow‑up. These findings confirm the feasibility of PPI deprescribing and provide relevant insights for patient counselling and expectation management during deprescribing phases.

Event

UEG Week Barcelona 2026

Topics

Stomach & H. Pylori Oesophagus

Submission format

Abstract

Session

Anti-secretory therapy: Evolving standards and future horizons

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

Desmoplasia in liver cancer: translating tumour microenvironment insights into clinical practice

Desmoplasia in liver cancer: translating tumour microenvironment insights into clinical practice

Silvia Affò Silvia Affò

Is ageing a metabolic disease?

Is ageing a metabolic disease?

Amalia Gastaldelli Amalia Gastaldelli

Metabolic syndrome

Metabolic syndrome

Helena Cortez-Pinto Helena Cortez-Pinto

Fatty pancreas

Fatty pancreas

Miroslav Vujasinovic Miroslav Vujasinovic

THE PEPPER TRIAL: WHAT TO EXPECT WHEN STOPPING CHRONIC PROTON PUMP INHIBITOR THERAPY IN PRIMARY CARE PATIENTS

THE PEPPER TRIAL: WHAT TO EXPECT WHEN STOPPING CHRONIC PROTON PUMP INHIBITOR THERAPY IN PRIMARY CARE PATIENTS

Florencia Carbone Florencia Carbone, Jan Tack, Annouschka Laenen, Karen Van den Houte, Janne Scheepers

INCRETIN-BASED THERAPIES IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS: COMPARATIVE HISTOLOGIC EFFICACY AND INTERNATIONAL GUIDELINE DISCORDANCE

INCRETIN-BASED THERAPIES IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS: COMPARATIVE HISTOLOGIC EFFICACY AND INTERNATIONAL GUIDELINE DISCORDANCE

Tyler Black Tyler Black, Adam Edwards, Samuel Tarwater, Benjamin Hewitt, Paul Lamb, Travis Rutland, Beth Rutland, Rowan Bandaranaike

UEG Poster
New
Standard Poster
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

INCRETIN-BASED THERAPIES IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS: COMPARATIVE HISTOLOGIC EFFICACY AND INTERNATIONAL GUIDELINE DISCORDANCE

Rowan Bandaranaike 1, Beth Rutland 2, Travis Rutland 2, Paul Lamb 2, Benjamin Hewitt 2, Samuel Tarwater 2, Adam Edwards 2, Tyler Black 2

Affiliations

1 Southeast Health, Dothan, United States

2 Digestive Health Specialists, Dothan, United States

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 30–38% of the European population, with steatohepatitis (MASH) driving cirrhosis and hepatocellular carcinoma.¹ Multiple incretin-based therapies have demonstrated histologic efficacy, yet no head-to-head trials exist and significant guideline discordance persists regarding patient selection and fibrosis thresholds. This creates an urgent unmet need for harmonised European guidance.

Aims & Methods

We aimed to evaluate comparative histologic efficacy of incretin-based therapies in MASH and analyse international guideline discordance to inform European practice. Phase 2b/3 RCTs, network meta-analyses, consensus reports, and guidelines (EASL-EASD-EASO, AASLD, ADA, 2026 Younossi global Delphi consensus) were reviewed through March 2026. Asian-Pacific society guidelines were also included for comparison. Recommendations were compared across treatment eligibility, fibrosis staging, cardiometabolic risk integration, and implementation feasibility.

Results

Phase 3 trials confirmed robust histologic efficacy. In ESSENCE, semaglutide 2.4 mg weekly achieved MASH resolution without fibrosis worsening in 62.9% versus 34.3% placebo (p<0.001) and fibrosis improvement in 36.8% versus 22.4% (p<0.001).² In SYNERGY-NASH, tirzepatide demonstrated dose-dependent MASH resolution (44–62% versus 10% placebo) with fibrosis improvement (51–55% versus 30%).³ Semaglutide failed to improve fibrosis in compensated cirrhosis, underpinning F2–F3 regulatory restrictions.⁴ Meta-analytic data confirmed benefits for MASH resolution (OR 3.48, 95% CI 2.69–4.51) and fibrosis regression (OR 1.79, 95% CI 1.37–2.35).⁵
A network meta-analysis of 29 RCTs (n=9,324) ranked pegozafermin (SUCRA 91.75), survodutide (SUCRA 90.87), and tirzepatide (SUCRA 84.70) highest for MASH resolution, while semaglutide ranked lower despite sole phase 3 regulatory data.⁶ This exposes a critical tension between comparative efficacy rankings and regulatory maturity, as agents with the strongest network rankings lack phase 3 confirmatory data for regulatory submission.
Guideline discordance emerged across three domains. First, EASL-EASD-EASO recommends incretin-based therapies within a weight-loss strategy before second-stage NIT evaluation, whereas AASLD mandates NIT-confirmed F2–F3 fibrosis (VCTE 8–15 kPa, ELF 9.2–10.5) before pharmacotherapy.⁴˒⁷ The 2026 Delphi consensus endorsed VCTE 10–20 kPa or ELF 9.2–11.3 as treatment-eligible thresholds.⁸ Second, European and ADA frameworks position these agents as dual cardiometabolic-hepatic therapies, while AASLD notes cardiovascular benefit in MASH remains presumptive.⁴˒⁹ Third, current approvals exclude F4 disease, leaving a guidance gap for patients receiving these agents for cardiometabolic indications. European implementation is further complicated by heterogeneity in NIT availability and reimbursement across healthcare systems.

Conclusion

Incretin-based therapies represent a paradigm shift in MASH, yet discordance between European metabolic-holistic and US fibrosis-mandatory approaches creates actionable clinical uncertainty for European hepatologists. An EASL-led European position statement integrating NIT-based staging, cardiometabolic profiling, and health-economic modelling is urgently needed to standardise patient selection and optimise equitable access across diverse European healthcare systems.

References

1. Tilg H, Moschen AR, Byrne CD, et al. MASLD in adults: a review. JAMA. 2026;335(2):163–74.

2. Sanyal AJ, Bedossa P, Engel SS, et al. Semaglutide in MASH. N Engl J Med. 2025;392(21):2089–99.

3. Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for MASH with liver fibrosis. N Engl J Med. 2024;391(4):299–310.

4. Targher G, Tilg H, Byrne CD. MASLD. N Engl J Med. 2025;393(7):683–98.

5. Mantovani A, Petracca G, Csermely A, et al. GLP-1 RAs in MASH and fibrosis: meta-analysis. Liver Int. 2025;45(9):e70256.

6. Souza M, Al-Sharif L, Engel S, et al. Pharmacotherapies in MASH: network meta-analysis. Hepatology. 2025.

7. Bansal MB, Curry MP, Gawrieh S, et al. Semaglutide for MASH: AASLD guidance. Hepatology. 2025.

8. Younossi ZM, Razavizade M, Engel SS, et al. Global Delphi consensus in MASLD. Clin Gastroenterol Hepatol. 2026.

9. Cusi K, Budd J, Engel SS, et al. MASLD in diabetes: ADA consensus. Diabetes Care. 2025;48(7):1057–82.

Conference

UEG Week Barcelona 2026

Topics

Hepatobiliary

Submission format

Abstract

Session

LIVER (Posters)

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

Desmoplasia in liver cancer: translating tumour microenvironment insights into clinical practice

Desmoplasia in liver cancer: translating tumour microenvironment insights into clinical practice

Silvia Affò Silvia Affò

Is ageing a metabolic disease?

Is ageing a metabolic disease?

Amalia Gastaldelli Amalia Gastaldelli

Metabolic syndrome

Metabolic syndrome

Helena Cortez-Pinto Helena Cortez-Pinto

Fatty pancreas

Fatty pancreas

Miroslav Vujasinovic Miroslav Vujasinovic

THE PEPPER TRIAL: WHAT TO EXPECT WHEN STOPPING CHRONIC PROTON PUMP INHIBITOR THERAPY IN PRIMARY CARE PATIENTS

THE PEPPER TRIAL: WHAT TO EXPECT WHEN STOPPING CHRONIC PROTON PUMP INHIBITOR THERAPY IN PRIMARY CARE PATIENTS

Florencia Carbone Florencia Carbone, Jan Tack, Annouschka Laenen, Karen Van den Houte, Janne Scheepers

INCRETIN-BASED THERAPIES IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS: COMPARATIVE HISTOLOGIC EFFICACY AND INTERNATIONAL GUIDELINE DISCORDANCE

INCRETIN-BASED THERAPIES IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS: COMPARATIVE HISTOLOGIC EFFICACY AND INTERNATIONAL GUIDELINE DISCORDANCE

Tyler Black Tyler Black, Adam Edwards, Samuel Tarwater, Benjamin Hewitt, Paul Lamb, Travis Rutland, Beth Rutland, Rowan Bandaranaike

The global reference point for the digestive health community

Platform Publisher

United European Gastroenterology

Wickenburggasse 1 1080 Vienna, Austria

Contact us

support@ueg.eu

ueg.eu

T: +43 1 997 1639

Legal

Terms & Conditions

Imprint

Privacy Policy

Explore

My Bookmarks

My recommendations

My fields of interest

© 2026 United European Gastroenterology

Change fields of interest

These fields are selected based on the interests in your myUEG profile.
Click the item to unselect it. You can select multiple items.